ERBB2 and breast cancer: They developed an FSP1‐Cre transgenic mice in which expression of the Cre recombinase was driven by a 3.1‐kb fragment of the FSP1 promoter (Fsp1‐Cre‐BGH) and crossed this mouse model with three different oncogene‐driven mammary tumor models (WAP‐Myc, MMTV‐PyMT, and MMTV‐Neu) to search for EMT activation in distant lung metastases (Trimboli et al., 2008).